Human Papillomavirus Same Genotype Persistence and Risk: A Systematic Review.
Journal
Journal of lower genital tract disease
ISSN: 1526-0976
Titre abrégé: J Low Genit Tract Dis
Pays: United States
ID NLM: 9704963
Informations de publication
Date de publication:
01 Jan 2021
01 Jan 2021
Historique:
pubmed:
27
10
2020
medline:
9
9
2021
entrez:
26
10
2020
Statut:
ppublish
Résumé
The aim of the study was to examine whether high-grade cervical intraepithelial neoplasia (CIN) was more closely associated with human papillomavirus (HPV) same-genotype persistence (SGTP) versus clearance of prior infection with a subsequent infection by a new genotype (genotype switch [GS]), clearance of HPV infection, or acquisition of a new HPV infection after a negative infection status, during a follow-up testing subsequent to abnormal screening results. MEDLINE, Cochrane Library, Health Technology Assessment, and clinicaltrials.gov were searched from January 2000 to July 2019 for prospective controlled trials and observational studies of women and retrospective studies using HPV assays with extended- or full-genotype reporting. The primary outcome was high-grade CIN after at least 2 rounds of testing. Overall quality of evidence for the risk estimate outcomes was assessed. Of the 830 identified abstracts, 66 full-text articles were reviewed, and 7 studies were included in the synthesis. The study protocol was registered with the PROSPERO International Prospective Register of Systematic Reviews (CRD42018091093). Continued HPV-positive women falls in 2 equally large groups: SGTP and GS. Sensitivity, positive predictive value, and positive likelihood ratio of SGTP were significantly higher than for GS. Human papillomavirus genotypes may be ranked into 3 tiers (immediate colposcopy, follow-up testing, return to routine screening), according to associated risk of persistence for high-grade CIN and to prevailing clinical action thresholds. There is moderately high-quality evidence to support the clinical utility of SGTP to improve risk discrimination for high-grade CIN compared with qualitative HPV testing without genotype-specific information.
Identifiants
pubmed: 33105450
pii: 00128360-202101000-00005
doi: 10.1097/LGT.0000000000000573
pmc: PMC7748037
doi:
Types de publication
Journal Article
Systematic Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
27-37Informations de copyright
Copyright © 2020 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the ASCCP.
Déclaration de conflit d'intérêts
D.S.G. and J.C.A. were full-time employees of Becton, Dickinson and Company. M.T.S. has in the past served as a paid advisor to Roche and received honoraria from Roche and BD. J.B. is the principal investigator of studies supported with reagents and limited co-funding to his institution by BD Diagnostics, Agena Bioscience, Genomica SAU, LifeRiver Biotech, and QIAGEN. He has received honoraria for lectures from BD Diagnostics and Hologic. J.B. is appointed member of the National Danish Cervical Screening Committee by the Danish Health Authority and a member of the regional cervical screening steering committee of the Capital Region of Denmark. The other authors have declared they have no conflicts of interest.
Références
Chen HC, Schiffman M, Lin CY, et al. Persistence of type-specific human papillomavirus infection and increased long-term risk of cervical cancer. J Natl Cancer Inst 2011;103:1387–96.
Schiffman M, Herrero R, Desalle R, et al. The carcinogenicity of human papillomavirus types reflects viral evolution. Virology 2005;337:76–84.
Marks MA, Castle PE, Schiffman M, et al. Evaluation of any or type-specific persistence of high-risk human papillomavirus for detecting cervical precancer. J Clin Microbiol 2012;50:300–6.
Matsumoto K, Oki A, Furuta R, et al. Predicting the progression of cervical precursor lesions by human papillomavirus genotyping: a prospective cohort study. Int J Cancer 2011;128:2898–910.
Nakamura Y, Matsumoto K, Satoh T, et al. HPV genotyping for triage of women with abnormal cervical cancer screening results: a multicenter prospective study. Int J Clin Oncol 2015;20:974–81.
Bonde JH, Sandri MT, Gary DS, et al. Clinical utility of human papillomavirus genotyping in cervical cancer screening: a systematic review. J Low Genit Tract Dis 2020;24:1–13.
International Agency for Research on Cancer. Human papillomaviruses. IARC Monogr Eval Carcinog Risks Hum 2012;100B:255–314.
Schiffman M, Castle PE, Jeronimo J, et al. Human papillomavirus and cervical cancer. Lancet 2007;370:890–907.
Schiffman M, Clifford G, Buonaguro FM. Classification of weakly carcinogenic human papillomavirus types: addressing the limits of epidemiology at the borderline. Infect Agent Cancer 2009;4:8.
Castle PE. Invited commentary: is monitoring of human papillomavirus infection for viral persistence ready for use in cervical cancer screening? Am J Epidemiol 2008;168:138–44; discussion 45-8.
Koshiol J, Lindsay L, Pimenta JM. Persistent human papillomavirus infection and cervical neoplasia: a systematic review and meta-analysis. Am J Epidemiol 2008;168:123–37.
Kovacs K, Varnai AD, Bollmann M, et al. A 7.5-year prospective study of longer than 18 months type-specific human papillomavirus persistence in a routine cytology-based cervical screening population of about 31,000 women in West Germany. Eur J Cancer Prev 2009;18:307–15.
Munoz N, Castellsague X, de Gonzalez AB, et al. Chapter 1: HPV in the etiology of human cancer. Vaccine 2006;24(suppl 3):S3/1–10.
Munoz N, Hernandez-Suarez G, Mendez F, et al. Persistence of HPV infection and risk of high-grade cervical intraepithelial neoplasia in a cohort of Colombian women. Br J Cancer 2009;100:1184–90.
Rodriguez AC, Schiffman M, Herrero R, et al. Longitudinal study of human papillomavirus persistence and cervical intraepithelial neoplasia grade 2/3: critical role of duration of infection. J Natl Cancer Inst 2010;102:315–24.
Walboomers JM, Jacobs MV, Manos MM, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 1999;189:12–9.
Cuschieri KS, Cubie HA, Whitley MW, et al. Persistent high risk HPV infection associated with development of cervical neoplasia in a prospective population study. J Clin Pathol 2005;58:946–50.
Kjaer SK, van den Brule AJ, Paull G, et al. Type specific persistence of high risk human papillomavirus (HPV) as indicator of high grade cervical squamous intraepithelial lesions in young women: population based prospective follow up study. BMJ 2002;325:572.
Radley D, Saah A, Stanley M. Persistent infection with human papillomavirus 16 or 18 is strongly linked with high-grade cervical disease. Hum Vaccin Immunother 2016;12:768–72.
Rebolj M, Brentnall AR, Mathews C, et al; Group HPVPS. 16/18 genotyping in triage of persistent human papillomavirus infections with negative cytology in the English cervical screening pilot. Br J Cancer 2019;121:455–63.
Schlecht NF, Kulaga S, Robitaille J, et al. Persistent human papillomavirus infection as a predictor of cervical intraepithelial neoplasia. JAMA 2001;286:3106–14.
Schmeink CE, Melchers WJ, Siebers AG, et al. Human papillomavirus persistence in young unscreened women, a prospective cohort study. PloS one 2011;6:e27937.
Sundstrom K, Eloranta S, Sparen P, et al. Prospective study of human papillomavirus (HPV) types, HPV persistence, and risk of squamous cell carcinoma of the cervix. Cancer Epidemiol Biomarkers Prev 2010;19:2469–78.
Massad LS, Einstein MH, Huh WK, et al. 2012 updated consensus guidelines for the management of abnormal cervical cancer screening tests and cancer precursors. J Low Genit Tract Dis 2013;17:S1–s27.
Demarco M, Egemen D, Raine-Bennett TR, et al. A study of partial human papillomavirus genotyping in support of the 2019 ASCCP Risk-Based Management Consensus Guidelines. J Low Genit Tract Dis 2020;24:144–7.
Egemen D, Cheung LC, Chen X, et al. Risk estimates supporting the 2019 ASCCP Risk-Based Management Consensus Guidelines. J Low Genit Tract Dis 2020;24:132–43.
Katki HA, Gage JC, Schiffman M, et al. Follow-up testing after colposcopy: five-year risk of CIN 2+ after a colposcopic diagnosis of CIN 1 or less. J Low Genit Tract Dis 2013;17:S69–77.
Katki HA, Schiffman M, Castle PE, et al. Five-year risks of CIN 3+ and cervical cancer among women who test Pap-negative but are HPV-positive. J Low Genit Tract Dis 2013;17:S56–63.
Clarke MA, Darragh TM, Nelson E, et al. Reporting and assessing the quality of diagnostic accuracy studies for cervical cancer screening and management. J Low Genit Tract Dis 2020;24:157–66.
Perkins RB, Guido RS, Castle PE, et al. 2019 ASCCP Risk-Based Management Consensus Guidelines for Abnormal Cervical Cancer Screening Tests and Cancer Precursors. J Low Genit Tract Dis 2020;24:102–31.
Schiffman M, Wentzensen N, Perkins RB, et al. An introduction to the 2019 ASCCP Risk-Based Management Consensus Guidelines. J Low Genit Tract Dis 2020;24:87–9.
Schiffman M, Wentzensen N, Khan MJ, et al. Preparing for the next round of ASCCP-sponsored cervical screening and management guidelines. J Low Genit Tract Dis 2017;21:87–90.
Stockdale CK. ASCCP president 2019-2020 vision. J Low Genit Tract Dis 2019;23:187.
Bottari F, Iacobone AD, Passerini R, et al. Human papillomavirus genotyping compared with a qualitative high-risk human papillomavirus test after treatment of high-grade cervical intraepithelial neoplasia: a systematic review. Obstet Gynecol 2019;134:452–62.
Fu T-CJ, Carter JJ, Hughes JP, et al. Re-detection vs. new acquisition of high-risk human papillomavirus in mid-adult women. Int J Cancer 2016;139:2201–12.
Gravitt PE, Rositch AF, Silver MI, et al. A cohort effect of the sexual revolution may be masking an increase in human papillomavirus detection at menopause in the United States. J Infect Dis 2013;207:272–80.
Sahlgren H, Elfstrom KM, Lamin H, et al. Colposcopic and histopathologic evaluation of women with HPV persistence exiting an organized screening program. Am J Obstet Gynecol 2020;222:253.e1–8.
Rebolj M, Bonde J, Preisler S, et al. Human papillomavirus assays and cytology in primary cervical screening of women aged 30 years and above. PLoS One 2016;11:e0147326.
Moher D, Liberati A, Tetzlaff J, et al; PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 2009;6:e1000097.
Eden J, Levit L, Berg A, et alInstitute of Medicine (US) Committee on Standards for Systematic Reviews of Comparative Effectiveness Research, eds. In: Finding What Works in Health Care: Standards for Systematic Reviews . Washington, DC: National Academies Press (US); 2011.
Booth A, Clarke M, Ghersi D, et al. An international registry of systematic-review protocols. Lancet 2011;377:108–9.
Jaisamrarn U, Castellsague X, Garland SM, et al. Natural history of progression of HPV infection to cervical lesion or clearance: analysis of the control arm of the large, randomised PATRICIA study. PLoS One 2013;8:e79260.
Skinner SR, Wheeler CM, Romanowski B, et al. Progression of HPV infection to detectable cervical lesions or clearance in adult women: analysis of the control arm of the VIVIANE study. Int J Cancer 2016;138:2428–38.
Arbyn M, Depuydt C, Benoy I, et al. VALGENT: a protocol for clinical validation of human papillomavirus assays. J Clin Virol 2016;76(suppl 1):S14–21.
Naaktgeboren CA, de Groot JA, van Smeden M, et al. Evaluating diagnostic accuracy in the face of multiple reference standards. Ann Intern Med 2013;159:195–202.
Whiting PF, Rutjes AW, Westwood ME, et al. QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies. Ann Intern Med 2011;155:529–36.
Castle PE, Rodriguez AC, Burk RD, et al; Proyecto Epidemiológico Guanacaste (PEG) Group. Short term persistence of human papillomavirus and risk of cervical precancer and cancer: population based cohort study. BMJ 2009;339:b2569.
Elfgren K, Elfstrom KM, Naucler P, et al. Management of women with human papillomavirus persistence: long-term follow-up of a randomized clinical trial. Am J Obstet Gynecol 2017;216:264.e1–7.
Gage JC, Schiffman M, Solomon D, et al. Comparison of measurements of human papillomavirus persistence for postcolposcopic surveillance for cervical precancerous lesions. Cancer Epidemiol Biomarkers Prev 2010;19:1668–74.
Gilham C, Sargent A, Kitchener HC, et al. HPV testing compared with routine cytology in cervical screening: long-term follow-up of ARTISTIC RCT. Health Technol Assess 2019;23:1–44.
Kitchener HC, Canfell K, Gilham C, et al. The clinical effectiveness and cost-effectiveness of primary human papillomavirus cervical screening in England: extended follow-up of the ARTISTIC randomised trial cohort through three screening rounds. Health Technol Assess 2014;18:1–196.
Kjaer SK, Frederiksen K, Munk C, et al. Long-term absolute risk of cervical intraepithelial neoplasia grade 3 or worse following human papillomavirus infection: role of persistence. J Natl Cancer Inst 2010;102:1478–88.
Sand FL, Munk C, Frederiksen K, et al. Risk of CIN3 or worse with persistence of 13 individual oncogenic HPV types. Int J Cancer 2019;144:1975–82.
Schünemann HJ, Oxman AD, Brozek J, et al. GRADE: assessing the quality of evidence for diagnostic recommendations. Evid Based Med 2008;13:162–3.
Walker JL, Wang SS, Schiffman M, et al. Predicting absolute risk of CIN3 during post-colposcopic follow-up: results from the ASCUS-LSIL Triage Study (ALTS). Am J Obstet Gynecol 2006;195:341–8.
Khan MJ, Castle PE, Lorincz AT, et al. The elevated 10-year risk of cervical precancer and cancer in women with human papillomavirus (HPV) type 16 or 18 and the possible utility of type-specific HPV testing in clinical practice. J Natl Cancer Inst 2005;97:1072–9.
Horn J, Denecke A, Luyten A, et al. Reduction of cervical cancer incidence within a primary HPV screening pilot project (WOLPHSCREEN) in Wolfsburg, Germany. Br J Cancer 2019;120:1015–22.
Goldman B, Rebolj M, Rygaard C, et al. Patterns of cervical coinfection with multiple human papilloma virus types in a screening population in Denmark. Vaccine 2013;31:1604–9.
Rositch AF, Koshiol J, Hudgens MG, et al. Patterns of persistent genital human papillomavirus infection among women worldwide: a literature review and meta-analysis. Int J Cancer 2013;133:1271–85.
Mittal S, Basu P, Muwonge R, et al. Risk of high-grade precancerous lesions and invasive cancers in high-risk HPV-positive women with normal cervix or CIN 1 at baseline-a population-based cohort study. Int J Cancer 2017;140:1850–9.
Mariani L, Sandri MT, Preti M, et al. HPV-testing in follow-up of patients treated for CIN2+ lesions. J Cancer 2016;7:107–14.
Kawaguchi R, Matsumoto K, Akira S, et al. Guidelines for office gynecology in Japan: Japan Society of Obstetrics and Gynecology (JSOG) and Japan Association of Obstetricians and Gynecologists (JAOG) 2017 edition. J Obstet Gynaecol Res 2019;45:766–86.